Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Marek’s disease and avian influenza vaccine developed
Scientists inserted avian influenza into the turkey herpesvirus that is used in Marek's disease vaccines.

Gene-editing technique faster than previous methods

A vaccine that offers birds protection against Marek’s disease and avian influenza has been developed by scientists at The Pirbright Institute.


Writing in the journal Vaccines, scientists describe how they used a gene-editing technique (CRISPR/Cas9 ) to insert avian influenza into the turkey herpesvirus (HVT) that is used in Marek’s disease vaccines.


The gene codes for haemagglutinin (HA) - an influenza protein that plays a vital role in the virus’ ability to infect host cells and a key target of the host immune response to block infection.


Professor Munir Iqbal, head of the Avian Influenza group at Pirbright, explains: “HVT is already widely used in vaccines against Marek’s disease and can be administered to eggs, enabling automated delivery and providing birds with protection from the day they hatch.

“The additional HA gene we have incorporated will be expressed by HVT when it replicates in host cells, meaning that a single dose of vaccine induces immunity against both viruses."


Compared to previous methods, the new technique is faster, more efficient, and will reduce the time it takes for poultry producers to update vaccine strains. This will enable a quicker response to disease outbreaks and provide better protection.


Prof Iqbal continued: “The genetic engineering process we have developed using CRISPR/Cas9 is far quicker and more efficient than previous technologies, as well as being very consistent and accurate. These attributes are essential for providing fast and reliable vaccine production to protect poultry.


“Improving how we make vaccines is critical for preventing avian influenza outbreaks. Our work could help reduce the spread of disease between birds and reduce the risk of infection for people who work closely with poultry."

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.